Institute for Health Services Research in Dermatology and Nursing, University Clinics of Hamburg, Hamburg, Germany.
Dermatology. 2010;221(3):236-42. doi: 10.1159/000320111.
The introduction of biological agents has considerably changed the treatment of moderate to severe psoriasis. So far only limited data on their cost-effectiveness exist.
Determination of the cost-effectiveness of biologicals from a German third payer's perspective, assessed over a 12-week period.
Efficacies of the biologicals were determined by a literature review. Treatment modalities were taken from the European S3 psoriasis guideline. Costs were calculated on the basis of the German physicians' fee schedule. Cost-effectiveness was determined and a sensitivity analysis performed.
Infliximab at a dose of 3 mg/kg was the most cost-effective agent, directly followed by adalimumab, infliximab 5 mg/kg and ustekinumab. The least cost-effective agent was etanercept 2 × 50 mg/week. Sensitivity analysis showed considerable overlap of the cost-effectiveness ratios.
Under the conditions of the German health care system, biological agents for psoriasis differ in their cost-effectiveness ratios. Differences are small, however. A major limitation of the study is the short time horizon of 12 weeks.
生物制剂的引入极大地改变了中重度银屑病的治疗方式。到目前为止，关于其成本效益的数据非常有限。
从德国第三方支付者的角度出发，评估生物制剂在 12 周内的成本效益。
通过文献回顾确定生物制剂的疗效。治疗方案取自欧洲 S3 银屑病指南。基于德国医生的收费标准计算成本。确定成本效益，并进行敏感性分析。
3mg/kg 剂量的英夫利昔单抗是最具成本效益的药物，其次是阿达木单抗、5mg/kg 剂量的英夫利昔单抗和乌司奴单抗。最不具成本效益的药物是依那西普 2×50mg/周。敏感性分析显示成本效益比有很大的重叠。
在德国医疗保健系统的条件下，用于银屑病的生物制剂在成本效益比方面存在差异。然而，差异很小。本研究的一个主要局限性是 12 周的时间跨度较短。
